Skip to main content

Table 2 Women’s preferences regarding risk-based screening and prevention for each hypothetical risk scenario

From: Dutch women’s intended participation in a risk-based breast cancer screening and prevention programme: a survey study identifying preferences, facilitators and barriers

  All women
N = 942
Low risk
N = 236
Average risk
N = 228
Moderate risk
N = 239
High risk
N = 239
Want to know breast cancer risk, n (%)a
 Yes 756 (80.3)         
 No 70 (7.4)         
 Don’t know 99 (10.5)         
 Missing value 17 (1.8)         
Willing to get mammogram, n (%) 727 (96.2)         
Willing to complete questionnaire, n (%) 725 (95.9)         
Willing to provide blood sample, n (%) 738 (97.6)         
Risk result in letter, n acceptable (%)a 621 (67.1) 199 (86.1) 160 (70.2) 144 (61.5) 118 (50.2)
Need for consultation, n yes (%)a 722 (76.6) 131 (56.7) 158 (70.2) 214 (91.5) 219 (93.2)
Preferred risk counsellor, n (%)b
 General practitioner 539 (57.2) 91 (38.6) 126 (55.3) 169 (70.7) 153 (64.0)
 Oncologist 293 (31.1) 38 (16.1) 58 (25.4) 94 (39.3) 103 (43.1)
 Nurse 93 (9.9) 21 (8.9) 24 (10.5) 24 (10.0) 24 (10.0)
 Geneticist 77 (8.2) 14 (5.9) 10 (4.4) 29 (12.1) 24 (10.0)
 Radiologist 64 (6.8) 11 (4.7) 15 (6.6) 24 (10.0) 14 (5.9)
 Radiographer 63 (6.7) 15 (6.4) 18 (7.9) 19 (7.9) 11 (4.6)
Use website, n yes (%)c 730 (79.0) 167 (72.6) 172 (76.4) 203 (86.8) 188 (80.0)
Supplemental screening, n yes (%)c 370 (39.3) 63d (27.4) 89e (39.6) 117e (50.0) 101f (43.0)
Preferred screening interval low risk
 2-year    116 (50.7)       
 3-year    30 (13.1)       
 4-year    30 (13.1)       
 5-year    13 (5.7)       
 Don’t know    18 (7.8)       
 Other    22 (9.6)       
Preferred screening start age low risk
 50 years    64 (27.9)       
 51 years    3 (1.3)       
 52 years    12 (5.2)       
 53 years    8 (3.5)       
 54 years    7 (3.1)       
 55 years    37 (16.2)       
 56 years    3 (1.3)       
 57 years    3 (1.3)       
 58 years    3 (1.3)       
 59 years    1 (0.4)       
 60 years    13 (5.7)       
 Other    43 (18.8)       
 Don’t know    32 (14.0)       
Preferred screening interval high risk
 6-month          31 (30.7)
 1-year          51 (50.5)
 18-month          1 (1.0)
 2-year          4 (4.0)
 Don’t know          6 (5.9)
 Other          8 (7.9)
Preferred screening start age high risk
 40 years          60 (59.4)
 42 years          1 (1.0)
 45 years          5 (5.0)
 50 years          2 (2.0)
 Other          22 (21.8)
 Don’t know          11 (10.9)
Increased breast self-exam (% yes)g 597 (64.7) 65 (28.4) 132 (58.7%) 204 (87.2) 196 (83.4)
Change diet (%)h
 Yes 445 (47.2) 101 (42.8) 91 (39.9) 129 (54.0) 124 (51.9)
 No 9 (1.0) 6 (2.5) 0 (−) 1 (0.4) 2 (0.8)
 No, not required 362 (38.4) 98 (41.5) 105 (46.1) 78 (32.6) 81 (33.9)
 Don’t know 40 (4.2) 8 (3.4) 11 (4.8) 8 (3.3) 13 (5.4)
 Other 61 (6.5) 14 (5.9) 15 (6.6) 18 (7.5) 14 (5.9)
Change exercise habits (%)h
 Yes 307 (32.6) 64 (27.1) 71 (31.1) 86 (36.0) 86 (36.0)
 No 119 (12.6) 42 (17.8) 30 (13.2) 25 (10.5) 22 (9.2)
 No, not required 332 (35.2) 86 (36.4) 83 (36.4) 78 (32.6) 85 (35.6)
 Don’t know 84 (8.9) 17 (7.2) 19 (8.3) 26 (10.9) 22 (9.2)
 Other 75 (8.0) 18 (7.6) 19 (8.3) 19 (7.9) 19 (7.9)
Change alcohol consumption (%)h
 Yes 277 (29.4) 58 (24.6) 59 (25.9) 71 (29.7) 89 (37.2)
 No 55 (5.8) 25 (10.6) 12 (5.3) 10 (4.2) 8 (3.3)
 No, not required 531 (56.4) 130 (55.1) 142 (62.3) 136 (56.9) 123 (51.5)
 Don’t know 30 (3.2) 9 (3.8) 4 (1.8) 10 (4.2) 7 (2.9)
 Other 24 (2.5) 5 (2.1) 5 (2.2) 7 (2.9) 7 (2.9)
Willing to consider medication (% yes)i 241 (58.2)      112 (53.8) 129 (62.6)
Tamoxifen preference, n (%)j
 Pill 171 (35.7)      90 (37.7) 81 (33.9)
 Cream 125 (26.2)      59 (24.7) 66 (27.6)
 No preference 93 (19.5)      42 (17.6) 51 (21.3)
 Neither 47 (9.8)      26 (10.9) 21 (8.8)
 Don’t know 32 (6.7)      17 (7.1) 15 (6.3)
Anecdotal knowledge of tamoxifen (% yes)j 55 (11.8)      22 (9.4) 33 (14.1)
  1. a17 women with missing value (1.8%) were excluded; b multiple answers possible; c18 women with missing value (1.9%) were excluded; dbased on a 4-year screening interval; ebased on a 2-year screening interval; fbased on a 1-year screening interval; g19 women with missing value (2.0%) were excluded; h25 women with missing value (2.7%) were excluded; i64 women with missing value (13.4%) were excluded; j10 women with missing value (2.1%) were excluded